Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 2.86 percent increase over losses of $(0.70) per share from the same period last year.
Meta Platforms Stock Is Tumbling Thursday: What’s Going On?
Meta reported first-quarter revenue of $36.455 billion, which came in ahead of analyst estimates of $36.156 billion. The company also beat earnings estimates when it reported EPS of $4.71 versus estimates of $4.33, according to Benzinga Pro.
